MAGLUMI SARS-CoV-2 S-RBD IgG (CLIA)
Manufactured by Snibe Co., Ltd, China - www.snibe.com/
Device identification number
1299
CE Marking
✓Yes
HSC common list
×No
HSC mutual recognition
×No
Format
Automated, Manual
Target
Antibody, IgG
Specimen
Plasma, Serum
Commercial Status
Commercialised
Last Update
2021-05-10 01:04:00 CET
Assay Type
Immuno-Antibody
Method
CLIA
Measurement
Quantitative
Clinical Sensitivity
0-7days Post Onset of Symptoms: 74.5%; 8-14 days Post Onset of Symptoms: 97.9%; ? 15 days: 100%
Notes
Manual or automated other
The database contains publicly available In Vitro Diagnostic Medical Devices for COVID-19 and it is being updated periodically. Please note that additional performance (as retrieved from manufacturers web pages) is provided only for devices commercially available with CE-IVD mark. Acknowledgements